| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.8 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.8 |
| mRNA | AICAR | GDSC1000 | pan-cancer | AAC | 0.0073 | 0.8 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.0066 | 0.8 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.0079 | 0.8 |
| mRNA | N9-isopropylolomoucine | CTRPv2 | pan-cancer | AAC | 0.0077 | 0.8 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | -0.0073 | 0.8 |
| mRNA | SN-38 | GDSC1000 | pan-cancer | AAC | 0.0069 | 0.8 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | 0.037 | 0.8 |
| mRNA | JNK Inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.007 | 0.8 |